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This review summarizes data on expression level and localization, structure and functional properties of 
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on CYP2E1 expression inhibitors. The latest data on CYP2E1 expression regulation and degradation 
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Introduction. Monooxygenase cytochrome P450-de-
pendent system of microsomal haemoproteins is as­
sociated with endoplasmic reticulum membrane, plays 
an important role in the metabolism of a broad 
spectrum of both endogenous and exogenous com­
pounds with different chemical structure and regu­
lates their transformation to soluble and less toxic 
metabolites. Cytochromes P450 perform a diverse set 
of monooxygenation reactions including hydroxylati-
on, epoxidation, demethylation and heteroatom oxi­
dation. Mammalian CYP450s are responsible for me­
tabolism of most diverse xenobiotics — drug mole­
cules, environmental compounds and pollutants, and 
are required for the efficient elimination of foreign 
chemicals from the body. 
On the other hand, these enzymes also metabo-
lically activate biologically inert compounds to elec-
trophilic derivatives that can cause toxicity, cell death 
and cellular transformation resulting in cancer. Cyto­
chrome P450 monooxygenases are also involved in 
physiologically important pathways of synthesis of 
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steroid hormones, prostaglandins and vitamins. All 
P450 enzymes exhibit similarity in their structure and 
general mechanism of action; however, there are 
significant differences in the detailed function of 
individual enzymes as well as in the structures and 
properties of their active sites. Specific forms of P450 
exhibit distinct, but partially overlapping substrate 
specificities [1]. The hepatic cytochrome P450 sys­
tem, with numerous different P450 enzymes, is char­
acterized by its inducibility by a variety of endo­
genous and exogenous compounds. 
Cytochrome P4502E1 (CYP2E1) description. Cy­
tochrome P4502E1 (CYP2E1) is a specific induced by 
ethanol isozyme of cytochrome P450. Human CYP-
2E1 gene is located on the 10th chromosome (10q24.3-
qter), consists of 9 exones and 8 intrones, contains a 
typical TATA-box and spans 11413 base pairs of 
genomic DNA [2, 3]. Only one gene has been 
detected in the CYP2E subfamily in rat, mouse and 
man, while two genes were found in rabbit [2]. 
Human CYP2E1 is a membrane-bound protein with 
molecular weight of ~ 57 kDa. It consists of 493 
amino acid residues and is primarily associated with 
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endoplasmic reticulum membranes [4]. CYP2E1 is 
well conserved across mammalian species [5 ] and has 
been isolated and purified from the liver of many 
mammals including rabbit, rat, mouse, hamster, mon­
key and humans [6, 7]. The complete amino acid 
sequences were determined for rat and human CYP-
2E1 [6]. Both proteins contain 493 amino acids and 
calculated molecular masses of 56,634 and 56,916 Da, 
respectively. Human CYP2E1 shared 15 % nucleotide 
and 78 % amino acid similarities to the respective 
orthologous rat cDNA and deduced amino acid se­
quences [6]. Amino acid composition of CYP2E1 is 
similar to that of other cytochrome P450 isozymes: 
38 % hydrophobic, 13 % basic and 12 % acidic. 
Protein contains five Trp and four Cys residues [8 ]. 
The greater part (63.7 %) of CYP2E1 molecule has 
regular structure — a-helices of different length form 
52.5 % of amino acid sequence, and /?-sheets consti­
tute 11.2 % [9]. 
CYP2E1 three-dimensional structure is studied 
insufficiently due to the presence of hydrophobic 
N-terminal transmembrane anchor in the structure of 
all cytochrome P450 isoforms, and hydrophobic ami­
no acid residues on the protein surface, that leads to 
molecule aggregation in water solutions. The latter 
complicates crystallization of protein and definition of 
a three-dimensional structure by X-ray analysis. 
Three-dimensional structure models of CYP2E1 are 
constructed for the purpose of structure-based pre­
diction of CYP2E1 metabolism of diverse substrates 
[10]. To establish a three-dimensional structure of 
proteins that are difficult to dissolve in water solu­
tions, molecular modelling technique is widely uti­
lized. This approach includes search for the protein 
with known crystal structure with a relatively high 
degree of primary sequence homology with protein in 
question, and utilizing this protein as a template. 
Models of tertiary structure of human CYP2E1 were 
developed on the basis of CYP2E1 sequence align­
ments with crystallographic templates of known struc­
ture, including rabbit CYP2C5 [10, 11], human 
CYP2C9 [9] and bacterial CYP102 [4]. Alignment of 
CYP2E1 spatial structure model with structures of 
CYP2C5 and CYP2C9 template proteins is presented 
in Figure [9]. A relatively high degree of primary 
sequence homology (identity = 59 %), as expected for 
proteins of the same CYP family, ensured a straight­
forward generation of the three-dimensional model 
due to relatively few deletions and insertions of amino 
acid residues with respect to the CYP2C5 crystal 
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structure [10]. Following geometric and energetic 
assessments, the utility of the model was tested in 
structure-based predictions of metabolism. Interactive 
docking of a number of human CYP2E1 substrates: 
chlorzoxazone, p-nitrophenol, N-nitrosodimethylami-
ne, acetaminophen, caffeine, theophylline, and me-
thoxyfluranis is consistent with their known positions 
in CYP2E1-mediated metabolism, where specific in­
teractions with key active site amino acid side-chains 
appear to rationalize the binding and orientation of 
substrate molecules. The sequence alignment of hu­
man CYP2E1 revealed a relatively high degree of 
homology with mouse, rat and rabbit CYP2E1 (80.8, 
80.3, and 79.0 %) and indicated similarity of 90.0, 
92.0, and 90.0 %, respectively. The heme is placed 
between helix L on the side of the heme proximal to 
the surface of the protein and helix I in the interior 
of the protein. Coordination of heme iron by cysteine 
plays a prominent role in the CYP2E1 capacity to 
catalyze the scission of molecular oxygen bound to the 
sixth coordination site of the heme iron [11 ]. 
Little information is available on the active site 
topologies of the enzyme. Previously, it was suggested 
that the active site was restricted due to the limited 
size of known substrates. A model for the active site 
structure of human CYP2E1 based on the coordinates 
of cytochrome P450BM-3 crystal structure was pro­
posed. The predicted CYP2E1 active site model shows 
that the active site is small and contains mainly 
hydrophobic residues [12]. The active site of human 
CYP2E1 is sterically unhindered directly above the 
iron for a distance of 10 A. The substrate binding 
pocket is located on top of pyrrole rings A and D of 
the heme and the active site cavity is relatively open 
above pyrrole rings A and D [13]. The access to В 
and С rings is partially or completely blocked by 
protein side chains. The substrate binding cavity has 
a volume of 4717 A3. 
Amino acid residues within the putative active 
site of human CYP2E1, including those associated 
with the binding of substrates and inhibitors, are 
shown to correspond with those identified by site-
directed mutagenesis experiments [14]. Certain CYP-
2E1 amino acid residues were identified, which parti­
cipate in the binding of substrates and inhibitors — 
chlorzoxazone, p-nitrophenol, N-nitrosodimethylami-
ne, acetaminophen, caffeine, and theophylline. Mo­
lecular modelling of a predicted cytosolic domain of 
CYP2E1 resulted in identification of a putative ubi-
quitination-target/ substrate-interaction structure (re-
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sidues 317—340) [15]. Consequently, it was found 
that the CYP2E1 active site exhibits complementarity 
with the structural characteristics of known substrates 
and inhibitors of this enzyme, including their rela-
tively low molecular weights and disposition of hyd-
rogen bond-forming groups [4 ]. 
The expression and localization of CYP2E1. 
CYP2E1 is a clinically and toxicologically important 
isozyme and is constitutively expressed in the liver 
and many extrahepatic tissues [7, 16—18]. Using 
specific antibodies in immunoblots and RT-PCR 
mRNA analysis it was shown that CYP2E1 expression 
level is significantly lower in extrahepatic tissues, in 
particular, kidney, pancreas, lung, nasal and intes-
tinal mucosa, as well as in distinct brain and heart 
Alignment of CYP2E1 spatial 
structure model with structures 
of CYP2C5 and CYP2C9 tem-
plate proteins based on loca-
tions of Ca atoms in their poly-
peptide frames. a-Helices are 
shown in black, /3-folds — in 
dark grey, and polypeptide 
chain irregular sites — in grey. 
? «-Helices participating in ac-
tive site formation are also hi-
ghlighted separately. Three-
dimensional structure model of 
human CY2E1 was constructed 
using the Web-servers ESy-
Pred3D and Swiss-Model. This 
figure was prepared using 
Swiss-PDB Viewer 3.7 software 
[9] 
regions [7, 17—22]. There also appear to be signi-
ficant sex differences in the expression of CYP2E1. 
In particular, it was demonstrated that CYP2E1 
expressed in higher levels in male as compared to 
female rats [23 ]. 
Recent studies employing immunohistochemical 
techniques and Western blot analysis have shown that 
constitutive expression of CYP2E1 protein is predo-
minantly restricted to the perivenous region of the 
liver acinus [7, 16]. Microsomes isolated from the 
pericentral region of the liver display increased con-
tent of CYP2E1 and elevated catalytic activity to-
wards effective substrates for CYP2E1 such as N-
dimethylnitrosamine, as compared with periportal 
microsomes [24]. Immunohistochemical analysis re-
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vealed a 30-fold higher concentration of CYP2E1 in 
the centrilobular than in the periportal regions of the 
rat liver [25]. Results from in situ hybridization and 
run off experiments indicate that this regioselectivity 
is caused by a higher rate of gene transcription in the 
perivenous hepatocytes [16]. Quantitative image ana­
lysis demonstrated that CYP2E1 mRNA transcripts 
content in perivenous hepatocytes was significantly 
higher than in midzonal and periportal cells (18.3±1; 
9.5±2 and 3.1 ±2), respectively [26]. The hetero­
geneous distribution of CYP2E1 was also observed in 
cells isolated from either region and correlated to the 
relative content of CYP2E1 mRNA in the two cell 
types [25]. CYP2E1 transcription level appears to be 
activated by factors that are selectively expressed in 
the perivenous hepatocytes [16]. 
CYP2E1 catalytic activity in certain liver regions 
also varies significantly. Low Km dimethylnitrosamine 
demethylase activity (but not high Km activity) as well 
as the oxidation of aniline and p-nitrophenol was 2-
to 3-times higher in pericentral compared to periportal 
microsomes. Oxidation of aniline and p-nitrophenol 
was elevated in pericentral hepatocytes compared with 
periportal hepatocytes to the same extent as in the 
isolated microsomes [24]. The regiospecific exp­
ression, induction and increased catalytic activity of 
CYP2E1 may explain why several hepatotoxins, kno­
wn to be metabolized by this isozyme, primarily 
damage the centrilobular region in the liver [25, 27 ]. 
Tissue-specific differences in CYP2E1 expression can 
affect extrahepatic toxicity or carcinogenicity because 
of chemical activation of xenobiotics in target areas 
[19]. 
In hepatocytes CYP2E1 is predominantly as­
sociated with endoplasmic reticulum membrane. Low 
levels of CYP2E1 are expressed in many other 
hepatocyte compartments: in mitochondria, Golgi ap­
paratus, lysosomal vesicles and in the plasma mem­
brane [28, 29]. 
The biochemical and toxicological properties of 
CYP2E1. Humans are exposed to over 70000 man-
made chemicals including drugs, food additives, her­
bicides, pesticides, and industrial agents. It is well 
established that environmental chemicals are the 
cause of numerous human diseases including cancer. 
In most cases, chemical carcinogens require metabolic 
activation, which is mainly achieved by cytochrome 
P450 enzymes. CYP2E1 is responsible for metabolism 
of most xenobiotics, reduces toxicity of exogenous 
compounds, and is required for the efficient elimi-
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nation of foreign chemicals from the body [30]. 
Alterations in the level of CYP2E1 might influence 
the health effects of the environmental pollutants 
[31 ]. DNA modification and cancers can result from 
exposure to endogenous and exogenous chemicals and 
their metabolism to non-covalently bound products 
[32]. Most of the CYP2E1-catalyzed reactions are 
oxidations [30, 33, 34]. CYP2E1 is involved in 
metabolism of more than 100 endogenous and exo­
genous low-molecular hydrophobic toxicologically 
dangerous compounds with different structures: a 
wide variety of therapeutic agents, protoxicants and 
procarcinogens, and low molecular weight solvents [7, 
15, 17, 35]. This enzyme is responsible for the 
bioactivation and detoxification of a variety of xeno­
biotics present in food, organic solvents, tobacco 
smoke, drugs, pesticides, environmental pollutants 
and alcoholic drinks [36]. Alcohols, especially etha-
nol, were the first substrates to be characterized for 
oxidation by the microsomal ethanol oxidizing system 
[37]. CYP2E1 substrates include several alcohols, 
aldehydes, ketones, ethers, aromatic compounds, ha-
logenated hydrocarbons, alkanes, alkenes, and fatty 
acids. CYP2E1-catalyzed metabolism may cause toxi­
city or DNA damage through the production of toxic 
metabolites, oxygen radicals, and lipid peroxidation 
[38]. For example, it was demonstrated that CYP2E1 
is the major determinant of in vivo benzene metabo­
lism and benzene-induced myelotoxicity in mice [39 ]. 
CYP2E1 is involved in the process of oxidative 
transformation not only in detoxification, but also in 
metabolic bioactivation of many substrates, thus being 
of importance in the activation of many chemicals to 
cytotoxic, mutagenic or carcinogenic products [7, 40]. 
It contributes to activation of many procarcinogens 
and several drugs to highly reactive metabolites [7, 
17, 30, 32, 33, 38]. CYP2E1 participates in a-C-
hydroxylation, ш-hydroxylation, N-dealkylation of 
nitrosamine derivatives including N-nitrosodialkyl-
amines and tobacco-smoke-related nitrosamines in 
human liver microsomes [41]. In particular, the 
tobacco carcinogens 4- (methylnitrosamino) -1 - (3-py-
ridyl)-l-butanone and N-nitrosonornicotine require 
a-carbon hydroxylation in order to exert their carci­
nogenic effects. The tobacco carcinogen 4-(methyl­
nitrosamino) -1 - (3-pyridyl) -1 -butanone is enzymati-
cally activated by the hydroxylation of the a-methyl 
and a-methylene groups, leading to the formation of 
reactive products which can pyridyloxobutylate and 
methylate DNA, respectively [42]. CYP2E1 is invol-
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ved in the bioactivation of various other compounds 
present in tobacco smoke, for example, acrolein and 
1,3-butadiene [20]. CYP2E1 enzyme is a major 
catalyst for metabolic activation of N-nitrosodial-
kylamines involved in N-demethylation of nitroso-
amines — N-nitrosodimethylamine, N-nitrosomethyl-
amine and N-nitrosoethylamine -— to toxic, mutagenic 
and carcinogenic metabolites. The activation of N-
nitrosodimethylamine and N-nitrosonornicotine by 
liver microsomes was suggested to be catalyzed more 
actively by CYP2E1 than by other P450 enzymes 
because the activities were well correlated with N-
nitrosodimethylamine N-demethylation and aniline 
p-hydroxylation in human hepatocytes [41 ]. 
Liver microsomes from control rats metabolize at 
variable metabolic rates eight N-nitrosodi-n-alkyl-
amines, including five symmetrical (N-nitroso-dime-
thyl, -diethyl, -dipropyl, -dibutyl and -diamylamines) 
and four asymmetrical (N-nitrosomethylethyl, me-
thylpropyl, methylbutyl, and methylamylamines), in­
to aldehydes. The longer the alkyl chain of sym­
metrical N-nitrosamines, the smaller was the metabo­
lic rate of the corresponding aldehyde formation [43 ]. 
The human liver microsomes also catalyzed the deal-
kylation and denitrosation of other nitrosamines exa­
mined. The rates of product formation and the ratios 
of denitrosation to dealkylation varied with the struc­
tures and concentrations of the substrates as well as 
with the microsomal samples tested [44]. At a con­
centration of 0.2 mM N-nitrosodimethylamine, the 
rates of denitrosation (nitrite formation) were 5 to 
10 % of those of demethylation (formaldehyde for­
mation); the ratio of denitrosation to demethylation 
increased with increases in N-nitrosodimethylamine 
concentration. The rates of product formation of the 
samples ranged from 0.18 to 2.99 nmol formaldehy­
de-min'^mg"1 microsomal protein (median, 0.53 
nmol) [44]. 
Purified human liver CYP2E1 and human liver 
microsomes catalyzed the rearrangement of 2,6-di-
methylaniline to 4-amino-3,5-dimethylphenol. It is 
indicated by the occurrence of hemoglobin adducts of 
2,6-dimethylaniline [45]. 
It was found that CYP2E1 is the only enzyme 
responsible for epoxidation of acrylonitrile — suspec­
ted human carcinogen. It is demonstrated that 
CYP2E1 -mediated oxidation is a prerequisite for 
acrylonitrile metabolism to cyanoethylene oxide or 
cyanide formation, and this pathway is exclusively 
catalyzed by CYP2E1. It is confirmed that cyanide 
plays an essential role in the causation of the acute 
toxicity/mortality of acrylonitrile [46 ]. 
CYP2E1 also plays an important role in omega-
and (omega-l)-hydroxylations of fatty acids. Three 
parameters were studied: alkyl chain length, presence 
and configuration of double bond(s) in the alkyl 
chain, and involvement of carboxylic function in the 
fatty acid binding inside the access channel of P450 
active site. The total rate of metabolite formation 
decreased when increasing the alkyl chain length of 
saturated fatty acids from CI2 to С16. The double 
bond configuration did not modify the ability of fatty 
acid hydroxylation significantly. However, unsatu­
rated fatty acids, such as oleic, elaidic and linoleic 
acids, were omega- and (omega-l)-hydroxylated with 
efficiency at least similar to palmitic acid [47 ]. 
CYP2E1 is involved in metabolism of two hepa-
totoxic solvents — N,N-dimethyl- and N,N-diethyl-
formamide. In the N,N-dimethylformamide metabo­
lism the role of CYP2E1 is crucial and its expression 
may be an important factor in determining the 
susceptibility of humans to this solvent [48 ]. More­
over, CYP2E1 plays a major role in activation of other 
procarcinogenes such as benzene, urethane and sty-
rene [49]. 
CYP2E1 also catalyzes the oxidation of low 
density lipoproteins. It is well established that low 
density lipoprotein oxidation is a major contributor to 
foam cell formation during early atherogenesis. It was 
concluded that low density lipoproteins can be oxi­
dized by CYP2E1. Due to their presence in arterial 
wall, their oxidation may have a physiopathological 
relevance to atherogenesis [50]. In addition to the 
rather classical oxidations, P450s also catalyze less 
generally discussed reactions including reduction, 
desaturation, ester cleavage, ring expansion, ring 
formation, aldehyde scission, dehydration, ipso at­
tack, one-electron oxidation, coupling reactions, rear­
rangement of fatty acid and prostaglandin hydro­
peroxides, and phospholipase activity [33 ]. 
Metabolism of drugs by CYP2E1. CYP2E1 is 
involved in oxidative metabolism of clinically impor­
tant drugs: acetaminophen, caffeine, chlorzoxazone, 
anaesthetics (enflurane, halothane, sevoflurane) [5, 
17, 27, 51 ]. CYP2E1 is the principal enzyme respon­
sible for the metabolic conversion of these drugs to 
their active hepatotoxic metabolites. In particular, 
CYP2E1 is the rate-limiting enzyme that initiates the 
cascade of events leading to activation of acetami­
nophen to the hepatotoxic metabolite, N-acetyl-p-
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benzoquinoneimine and to increase of acetaminophen 
hepatotoxicity [52]. In the absence of this isozyme, 
acetaminophen toxicity will only be apparent at high 
concentrations [5, 30 ]. Hepatotoxicity is described in 
depth, as it is the most frequent clinical observation 
after acetaminophen-intoxication. In this context, co­
valent protein binding and oxidative stress are two 
important initial events highlighted [53]. 3'-Hyd-
roxyacetanilide — non-toxic regioisomer of the anal­
gesic acetaminophen — covalently binds to CYP2E1 
with preferential loss of its activity. CYP2E1 enzyme 
activity (p-nitrophenolhydroxylation) was decreased 
by 79 % in the mice treated with 3'-hydroxyace-
tanilide (600 mg/kg) [54 ]. Coadministration of aceta­
minophen with inhibitors of CYP2E1 prevented the 
development of acetaminophen-induced hepatotoxicity 
in rats. This calls for research for enzyme inhibitors 
that may be of therapeutic value [52 ]. 
CYP2E1 -mediated oxidation of halothane to a 
reactive intermediate trifluoroacyl chloride that cova­
lently binds to hepatic proteins forming trifluoro-
acetylated neoantigens is believed to be the initiating 
event in a complex immunologic cascade culminating 
in antibody formation and severe hepatic necrosis 
(«halothane hepatitis») in susceptible patients. Tri­
fluoroacyl chloride may also hydrolyze to the stable 
metabolite trifluoroacetic acid. CYP2E1 inactivation 
by disulfiram inhibits human halothane oxidation to 
trifluoroacetic acid in vitro and in vivo. Disulfiram 
inhibition of CYP2E1-mediated halothane oxidation 
appears to prevent hepatic proteins trifluoroacety-
lation in vivo [55]. 
Heavy consumption of alcohol, which results in 
CYP2E1 induction, increases individual susceptibility 
to toxic or carcinogenic effects of some drugs [51]. 
Chronic alcohol consumption may potentiate acetami­
nophen hepatotoxicity through enhanced formation of 
N-acetyl-p-benzoquinoneimine via induction of CYP-
2E1. However, CYP2E1 induction appears to be 
insufficient to explain the claimed magnitude of the 
interaction. CYP2E1 plays an important role in selec­
tive depletion of liver mitochondrial glutathione 
(GSH) by chronic ethanol [56 ]. Contrasting with the 
stimulating effects of chronic consumption, acute 
ethanol intake inhibits the metabolism of some drugs. 
CYP2E1 also activates some other commonly used 
drugs to their toxic metabolites, and promotes carci­
nogenesis [27]. 
СYP2E1-mediated reactions of reduction. CYP-
2E1 is effectively involved in reactions of reduction, 
in particular, carbon tetrachloride (CC14) -induced 
hepatotoxicity is one good example. CC14 is activated 
by CYP2E1 to form the trichloromethyl radical — 
CC13. It was found that elevated cytotoxicity of carbon 
tetrachloride plays an important role in the oxidative 
stress, induced by CYP2E1 [57]. Cytotoxic free 
radicals generated during the metabolism of carbon 
tetrachloride by CYP2E1 are thought to cause hepa­
totoxicity. Hsp70 mRNA level, a potential marker of 
oxidative stress, is significantly increased after carbon 
tetrachloride treatment. These results suggest that the 
oxidative stress induced by CYP2E1 plays an impor­
tant role in the increase of carbon tetrachloride 
cytotoxicity in CYP2El-overexpressing cells [57]. In 
addition, a dramatic decrease in CYP2E1-catalyzed 
p-nitrophenol activity and complete loss of iramu-
noreactive CYP2E1 were observed in mice after CC14 
treatment, suggesting that CYP2E1 was degraded 
during the process of carbon tetrachloride-induced 
hepatotoxicity [58]. 
In monolayer cultures of rat primary hepatocytes 
covalent binding of 14C-labeled metabolites of carbon 
tetrachloride was detected immediately after exposure 
to CC14. This radical can bind to cellular molecules 
(nucleic acid, protein, lipid), impairing crucial cellular 
processes such as lipid metabolism. The experiments 
confirm that covalent binding of the CC13 radical to 
cell components initiates inhibition of lipoprotein 
secretion and thus steatosis, whereas reaction with 
oxygen, to form CCI3-OO*, initiates lipid peroxi­
dation. These two processes are independent of each 
other, and the extent to which either process develops 
depends on partial oxygen pressure. The former 
process may result in adduct formation and, ul­
timately, cancer initiation, whereas the latter results 
in loss of calcium homeostasis, apoptosis and cell 
death [59]. 
CC14 continues to provide an important service 
today as a model substance to elucidate the mecha­
nisms of hepatotoxic effects such as fatty degene­
ration, fibrosis, hepatocellular death, and carcino­
genicity. Adduct formation between CC13 and DNA is 
thought to function as initiator of hepatic cancer. At 
the molecular level CC14 activates tumour necrosis 
factor (TNF)a, nitric oxide (NO), and transforming 
growth factors (TGF)-a and -/? in the cell, processes 
that appear to direct the cell primarily toward (self-) 
destruction or fibrosis [60 ]. 
CYP2E1 role in reactive oxygen radical ge­
neration. It is known, that CYP2E1 exhibits an 
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enhanced NADPH oxidase activity (NADPH oxi-
dation is uncoupled from substrate hydroxylation) as 
it appears to be poorly coupled with NADPH-cyto-
chrome P450 reductase [61 ]. CYP2E1 possesses a 
unique capacity to reduce molecular oxygen to highly 
reactive compounds — superoxide anion radical, sin-
gle oxygen, hydrogen peroxide [7, 62]. In the 
presence of certain iron complexes, CYP2E1 produces 
powerful oxidants such as hydroxyl radicals [40, 61 ]. 
It is known that due to steady-state in spin state 
cytochrome P450 may bind molecular oxygen and 
passage into high spin state only after binding the 
substrate. As compared to other cytochromes CYP2E1 
generates reactive oxygen species (ROS) even in the 
absence of substrate. Reactive oxyradicals might ini-
tiate membranous lipid peroxidation [63]. Increased 
rates of lipid peroxidation result in yielding products, 
mainly aldehydes, which activate immune cells for 
cytokine production and Ito cells for collagen for-
mation. CYP2E1 mediated formation of reactive lipid 
peroxidation products and a-hydroxyethyl radicals 
gives rise to protein adduct formation, some of which 
can cause autoimmune reactions [7]. This way of 
reactive oxygen species production has certain advan-
tages. In particular, degradation of the endoplasmic 
reticulum and other cell compartments in the presence 
of free radicals may constitute a physiological mecha-
nism of adaptation to changes in the environment. 
Metabolism of endogenous compounds by CYP-
2E1. Ethanol-inducible CYP2E1 also plays a signi-
ficant role in the metabolism of endogenous com-
pounds including fatty acids, ketone bodies and some 
cytotoxins [38, 62, 64]. CYP2E1 is involved in 
acetone catabolism and the cascade of events con-
nected with converting acetone to acetol and then to 
methylglyoxal, both intermediates in the gluconeo-
genic pathway. This was revealed through experi-
ments in vitro and in vivo [65]. CYP2E1 assumes a 
more important role under conditions of increased 
blood acetone levels, in particular after chronic con-
sumption of ethanol, and under states, which accom-
pany hyperketonemy and ketoacidosis. Glucose for-
mation from acetone may also contribute to the 
maintenance of a constant blood glucose level, but it 
seems to be only a minor source for that. Acetonemiae 
of endogenous origin are due to the increased rate of 
acetone production followed by an increase of degra-
ding capacity as CYP2E1 becomes induced. Exoge-
nous acetonemiae usually result from intoxications 
caused by either acetone itself or other exogenous 
compounds [64]. CYP2E1 also plays an important 
role in (D- and (a>-l)-hydroxylation of lauric and 
arachidonic acids [47, 66]. Hydroxylation of arachi-
donic acids results in the synthesis of some hydroxy-
eicosatetraenoic acids, which have physiological and 
pharmacological importance [5]. CYP2E1 substrates 
also include fatty acid hydrogen peroxides. Their 
oxidation leads to formation of aldehydes and alkanes 
[67]. 
On the other side, it is demonstrated that ani-
mals deficient in expression of the enzyme were 
fertile, developed normally, and exhibited no obvious 
phenotypic abnormalities, thus indicating that CYP-
2E1 has no critical role in mammalian development 
and physiology in the absence of external stimuli [5]. 
Markers for CYP2E1 activity. Enzymatic activi-
ties are routinely used to identify the contribution of 
individual forms of cytochrome P450 to a particular 
biotransformation. p-Nitrophenol O-hydroxylation 
has been widely used as a probe for measure of 
microsomal CYP2E1 catalytic activity [68, 69]. Sub-
strate markers of CYP2E1 catalytic activity are also 
aniline, although it is not specific for CYP2E1 [7, 
70], chlorzoxazone [15, 17, 71—73] and N-nitrosodi-
methylamine [24, 74]. Carbon tetrachloride-depend-
ent lipid peroxidation displays best correlation with 
CYP2E1 expression under all conditions [7, 57, 60]. 
In addition, trimethadione metabolism is a good 
CYP2E1 probe for liver disease in vivo and in vitro 
[17]. Chlorzoxazone was found to be oxidized only to 
6-hydroxychlorzoxazone in human liver microsomes. 
Results of steady-state kinetics are consistent with the 
view that only a single enzyme catalyzes the reaction. 
Rates of chlorzoxazone 6-hydroxylation in different 
human liver microsomal preparations were well cor-
related with levels of immunochemically measured 
CYP2E1 and rates of N-nitrosodimethylamine oxida-
tion [71 ]. In vivo chlorzoxazone 6-hydroxylation may 
have potential use as a non-invasive and selective test 
in estimating the expression and activity of human 
CYP2E1 and its significance as a risk factor in the 
toxicity and carcinogenicity of a number of solvents, 
nitrosamines, and drugs. Preliminary data on humans 
exposed to organic solvents indicates that chlorzo-
xazone metabolism may be a biomarker of occupa-
tional exposure to organic solvents [31 ]. 
Inter-individual variance of CYP2E1 activity in 
humans. Differences in biotransformation activities 
may alter the bioavailability or efficacy of drugs, 
provide protection from certain xenobiotic and envi-
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ronmental agents, or increase toxicity of others [75]. 
Significant inter-individual variability was established 
in expression gene, in the levels of CYP2E1 mRNA, 
protein and functional activity in human hepatic 
microsomes [75]. CYP2E1 protein content variation 
in individual human liver microsomes was 12 [75] to 
50 [7, 61, 76] times. Important inter-individual 
variability in the expression of CYP2E1 was observed 
and more than 30-fold differences in hepatic levels 
are reported [61, 77]. Rates of chlorzoxazone 6-
hydroxylation also vary considerably among human 
liver samples [71 ]. 
Cytochrome P450 enzymes are responsible for 
the majority of oxidations of drugs and other xeno-
biotics, and differences in their expression may 
directly produce inter-individual differences in sus-
ceptibility to compounds whose toxicity is modulated 
by these enzymes [75 ]. Analysis of variability in the 
levels of CYP2E1 mRNA, protein and functional 
activity in a human liver revealed that variation in 
CYP2E1 mRNA (18-fold) was greater than the varia-
tion seen in CYP2E1 protein (2-fold) and functional 
activity (4-fold) determined using two probe sub-
strates, chlorzoxazone and p-nitrophenol. Although 
protein and functional activity showed a significant 
correlation (r = 0.93 and r = 0.S3 for chlorzoxazone 
and p-nitrophenol, respectively), there was no cor-
relation between any of these parameters and mRNA 
levels [78]. The rates of product formation and the 
ratios of denitrosation to dealkylation varied with the 
structures and concentrations of the substrates as well 
as with the microsomal samples tested [44 ]. 
Inter-individual variability in CYP2E1 activity as 
measured in vivo in healthy subjects appears to be 
considerably less than that expected based on in vitro 
studies. Whether such variability is associated with 
individual susceptibility to CYP2E1-mediated toxicity 
remains to be determined [79]. The molecular me-
chanisms underlying inter-individual variability of 
CYP2E1 content and its catalytic activity are not 
established yet. Two major hypotheses were proposed 
for understanding this inter-individual variability — it 
may be of genetic origin or reflect the influence of 
environmental factors. 
Variability in expression gene, in the levels of 
CYP2E1 mRNA, protein and functional activity CYP-
2E1 may result from genomic polymorphisms. In 
accordance with this hypothesis, differences in the 
regulatory region of CYP2E1 are partially responsible 
for the in vivo intersubject variation in CYP2E1 
activity. The presence of the insertion mutation is 
associated with greater CYP2E1 metabolic ability, but 
only among individuals who either were obese or had 
recently consumed ethanol [80 ]. However, in another 
study the relationship between genotype and phe-
notypic catalytic activity of the enzyme has not been 
defined. The effects of specific dietary factors, other 
than ethanol, which have been shown in animal and 
in vitro studies to modulate CYP2E1 activity, are 
unknown in humans [79, 81]. No relationships were 
found between measures of CYP2E1 activity, both in 
vivo and in vitro, and genomic polymorphisms in 
CYP2E1 gene identified by RsallPstl and Dral res-
triction fragment length polymorphisms [82]. Accor-
ding to the second hypothesis, intersubject variation 
in CYP2E1 gene expression may be the consequence 
of complicated gene-environment interactions and ref-
lect their influence. Available studies indicate a wide 
variation in human CYP2E1 expression, which are 
very likely based on complex gene-environment inter-
actions. Major inter-ethnic differences are apparent 
on the genotyping and phenotyping levels [73]. 
More probably, the predominant reason consists 
in different degrees of CYP2E1 induction by sub-
strates-xenobiotics. Exogenous inducers elevate CYP-
2E1 protein levels through both increased trans-
lational efficiency and stabilization of the protein from 
degradation, which appears to occur primarily thro-
ugh ubiquitination and proteasomal degradation. 
CYP2E1 mRNA and protein levels are altered in 
response to multiple stimuli — genetic factors, age, 
weight, diet, and sex. 
Ethnic differences in CYP2E1 expression. The 
importance of the human isoform CYP2E1 for occu-
pational and environmental medicine is derived from 
its unique substrate spectrum that includes a number 
of important high-production chemicals, such as ali-
phatic and aromatic hydrocarbons, solvents and in-
dustrial monomers (i. e. alkanes, alkenes, aromatic 
and halogenated hydrocarbons) [73 ]. 
Possible consequences of differential inter-in-
dividual and inter-ethnic susceptibilities to harmful 
xenobiotic effects are related to individual expressions 
of clinical symptoms of chemical toxicity, to results of 
biological monitoring of exposed workers, and to the 
interpretation of results of epidemiological or mole-
cular-epidemiological studies. 
There are consistent ethnic differences in CYP-
2E1 enzyme expression, mostly demonstrated be-
tween European and Japanese populations, which 
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point to a major impact of genetic factors [73]. The 
most frequently studied genetic polymorphisms are 
the restriction fragment length polymorphisms 
Pstl/Rsal (mutant allele: CYP2E1*5B) located in the 
5'-flanking region of the gene, as well as the Dral 
polymorphism (mutant allele: CYP2E1*6) located in 
intron 6. These polymorphisms are partly related, as 
they form the common allele designated CYP2E1*5A 
[73]. 
The chlorzoxazone plasma concentrations after 
oral administration were significantly higher and its 
elimination rate slower in Japanese compared to 
Caucasian4 men. This was confirmed by in vitro 
studies with microsomes prepared from livers of 
individuals representative of two racial groups. CYP-
2E1 levels were lower (61 %, P< 0.002) and CYP-
2E1-mediated chlorzoxazone 6-hydroxylase (22 %, 
P < 0.001) and aniline 4-hydroxylase (35 %, P < 
< 0.0001) activities were reduced in Japanese pre­
parations compared to those from Caucasians [82]. 
Also, similarity in the metabolism of chlorzoxazone 
between Mexicans and European Americans suggests 
that the risk associated with CYP2E1-mediated acti­
vation of procarcinogens is not different between 
these two populations [83 ]. 
Specific inhibitors of CYP2E1. Ethanol-inducible 
CYP2E1 is responsible for metabolism of many xeno-
biotics which exert toxic effects in humans. Com­
pounds that inhibit CYP2E1 synthesis and activity 
are of particular interest, since they could be possibly 
utilized as preventive drugs to mitigate the harmful 
influence of unfavorable environmental factors. Spe­
cific inhibitors might constitute valuable tools in the 
elucidation of the pharmacological and toxicological 
roles of this isozyme in vivo. Selective inhibitors of 
CYP2E1 synthesis and catalytic activity are chloro-
methiazole, disulfiram, diallyl sulphide, diallyl sul­
foxide and diallyl sulfone, diallyl disulfide and al-
lylmethylsulfide, diethyldithiocarbamate, phenethyl-
isothiocyanate and 3,4- and 3,5-dichlorophenyl 
derivatives [84—86]. Recent results have shown that 
human CYP2E1 expression in vivo is almost com­
pletely inhibited in control subjects and in alcoholic 
patients treated with chloromethiazole [84]. Several 
CYP2E1 inhibitors are of significant therapeutic va­
lue. Polyenylphosphatidylcholine (PPC), an inno­
cuous mixture of polyunsaturated phosphatidylcho­
lines extracted from soybeans (and its active compo­
nent dilinoleoylphosphatidylcholine), were discovered 
to decrease CYP2E1 activity. PPC also opposes hepa­
tic oxidative stress and fibrosis [27 ]. Diallyl sulphide, 
diallyl sulfoxide and diallyl sulfone have been shown 
to reduce carbon tetrachloride-, N-nitrosodimethyl-
amine- and acetaminophen-induced toxicity in ro­
dents. All three inhibitors are substrates for CYP2E1. 
Moreover, these compounds have been shown to 
reduce the incidence of a multitude of chemically 
induced tumors in animal models [87]. Disulfiram 
inhibition of CYP2E1 -mediated halothane oxidation 
prevents hepatic protein trifluoroacetylation [55]. 
Chloromethiazole is an efficient transcriptional 
inhibitor of expression of rat hepatic ethanol-in­
ducible CYP2E1. Previously obtained data indicate 
that CYP2E1 gene is transcriptionally activated in 
response to medium change and that chloromethia­
zole, apart from being a transcriptional inhibitor of 
CYP2E1 expression, acts in addition as an efficient 
high-affinity post-translational inhibitor of CYP2E1, 
probably due to allosteric destabilization of the enzy­
me [84]. 4-Fold induction of CYP2E1 was observed 
after 3 days of starvation, accompanied by a similar 
increase in the level of the corresponding mRNA. 
Chloromethiazole specifically inhibited the elevation 
of CYP2E1 mRNA and protein [88]. In conclusion, it 
can be suggested that chloromethiazole might con­
stitute an efficient and specific inhibitor of CYP2E1 
expression suitable for in vivo experiments. 
Also, З'-hydroxyacetanilide has been previously 
studied as a nontoxic regioisomer of acetaminophen 
that covalently binds to CYP2E1 and strongly inhibits 
it with preferential loss of activity [54 ]. Inflammatory 
cytokines inhibit CYP2E1 expression by multiple 
mechanisms, including control of hepatocyte nuclear 
factor (HNF)-la function and regulation of other 
transcriptional factors acting on the CYP2E1 5'-
upstream regulatory region. Interestingly, IL-1/3, but 
not TNFa, was found to reduce HNF-la binding to 
the CYP2E1 promoter. In addition, regulation of 
factors of importance for the CYP2E1 mRNA stability 
may be involved [89]. 
Currently, constant search for new CYP2E1 
inhibitors is performed. For example, 3,4- and 3,5-
dichlorophenyl derivatives may be useful as potent 
CYP2E1 inhibitors [85]. CYP2E1 is one of the major 
cytochrome P450 forms whose expression is strongly 
inhibited by inflammatory cytokines in humans and 
rodents. All three cytokines — IL-1/3, TNFa, or IL-6 
decreased the CYP2E1 mRNA levels in Fao rat 
hepatoma cell line after 24 h. In contrast, significant 
inhibition of CYP2E1 protein was seen only after 72 
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h [54 ]. The effects of antifungals: bifonazole, econa-
zole, clotrimazole, ketoconazole, miconazole; CNS-
active drugs: chlorpromazine, desipramine, fluphe-
nazine, thioridazine; were investigated on the enzyme 
activities selective for CYP2E1. None of the drugs 
could be considered as a potent inhibitor of CYP2E1 
[68]. 
Mechanisms of CYP2E1 induction. It is known 
that monooxygenase cytochrome P450-dependent sys-
tem adapts to environmental changes easily due to 
isozymes induction by substrates. Understanding the 
mechanisms of isozyme induction is important for 
prediction of cytotoxic, mutagenic or carcinogenic 
action of many chemicals. Specific inductors of CYP-
2E1 activity are as follows: ethanol, imidazole, dime-
thylsulphoxide, 2-propanol, pyridine, isoniazid, ace-
tone, pyrazine, and pyrazole. Substrates-inductors of 
CYP2E1 are ethanol and acetone. 
On the contrary, imidazole induces CYP2E1, but 
is not its substrate. Acetaminophen, carbon tetra-
chloride, chlorzoxazone are CYP2E1 substrates but 
not inductors [7]. CYP2E1 induction by specific 
substrates has important physiological significance for 
the efficient elimination of foreign chemicals from the 
body. The induction of CYP2E1 protein expression by 
low-molecular compounds was demonstrated in vitro 
and in vivo. CYP2E1 expression increases in rat liver 
through administration of ethanol, acetone, pyrazole, 
and other related small molecular weight compounds. 
Administration of ethanol, dimethylsulphoxide, 2-
propanol or imidazole to rats caused 2—7-fold in-
creases in the level of hepatic ethanol-inducible cy-
tochrome P450 (P450j), without any concomitant 
enhancement of corresponding mRNA. All the com-
pounds were capable of stabilizing epnzyme in he-
patocyte cultures for at least three days, whereas 
mRNA rapidly disappeared [90, 91 ]. This induction 
is not the result of an increase in CYP2E1 mRNA, 
but could be due to either an increase in translation 
rate or a decrease in protein degradation. Immuno-
reactive CYP2E1 protein level and activity were 
significantly induced by isoniazid. At the same time 
two structural analogues of isoniazid — isonicotinami-
de and isonicotinic acid — were also tested and found 
to have a markedly decreased ability to induce 
CYP2E1 [70]. 
No changes were detected in hepatic CYP2E1 
mRNA levels at any time after acetone treatment, 
whereas rapid rises were observed in the microsomal 
amount of CYP2E1 protein and CYP2E1-catalyzed 
4-nitrophenol hydroxylase, and carbon-tetrachloride-
initiated lipid-peroxidation activities. However, CYP-
2E1-dependent catalytic activities declined much fas-
ter than the immunodetectable CYP2E1 protein, sug-
gesting that this isozyme is inactivated prior to 
degradation. Similar results were seen in primary 
hepatocyte cultures [28]. Treatment of primary cul-
tured rat hepatocytes with CYP2E1 inducers, i. e. 
ethanol, acetone, and pyrazine for 24 h, resulted in 
2—8-fold increases in CYP2E1 protein levels. Pyri-
dine addition to primary rat hepatocytes resulted in a 
3.5-fold enhancement in CYP2E1 protein expression 
in the absence of any pyridine-mediated increase in 
mRNA expression [92 ]. A single injection of pyridine 
(100 mg/kg, i. p.) increased CYP2E1 levels 2-, 3-
and 4-fold after 6, 10 and 24 h, respectively, relative 
to controls. Induction of CYP2E1 was dose-dependent 
over the range 10 to 200 mg/kg. Hybridization 
analysis failed to reveal an increase in CYP2E1 
mRNA in either total RNA or poly(A+) mRNA 
following pyridine treatment. Cycloheximide admi-
nistration prevented the induction of CYP2E1 by 
pyridine completely, whereas actinomycin D had no 
appreciable effect. These results suggest that induc-
tion of CYP2E1 at early times following acute pyri-
dine exposure involves protein synthesis possibly 
through increased translational efficiency [93 ]. 
A question of particular interest is the exact 
localization (liver region) of CYP2E1 expression in-
duction. Chronic ethanol exposure causes marked 
induction of the ethanol-inducible CYP2E1 in the 
centrilobular liver region. Analysis of cell lysates 
isolated from the periportal and perivenous region 
revealed that the increase in CYP2E1 mRNA by 
fasting occurred in the perivenous region [88 ]. CYP-
2E1 synthesis rate and catalytic activity are induced 
under a variety of physiological and pathophysio-
logical conditions such as fasting, diabetes, obesity, 
high fat diet, non alcohol induced steatohepatitis and 
also some environmental factors [16, 92, 94, 95]. 
Levels of CYP2E1 are elevated after acute and chronic 
alcohol treatment [40 ]. Diabetes has been reported to 
increase the expression of CYP2E1 mRNA and pro-
tein several-fold, and enhanced expression has been 
associated with elevated ketone bodies [96]. Adverse 
hepatic events associated with type II diabetes may be 
in part a result of enhanced CYP2E1 expression and 
activity [97]. 
CYP2E1 is reported to be induced by ketosis. 
The enzyme activities (aniline hydroxylase) in hepa-
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tic microsomes were elevated about 2—3-fold by 
feeding rats with a high fat diet for 3 days. The 
increases in enzyme activities were also accompanied 
by 3-fold increases in immunoreactive CYP2E1 prote­
in and its mRNA. Higher levels of CYP2E1 mRNA 
correlated positively (r = 0.73) with plasma concentra­
tions of acetoacetate and /ї-hydroxybutyrate. These 
data indicate that CYP2E1 induction during the 
ketosis caused by high fat feeding appears to be due 
to pretranslational activation and that is similar to the 
induction mechanism in fasted and diabetic animals 
[98]. 
It was observed that induction of CYP2E1 by 
many low-molecular-weight compounds elevates CYP-
2E1 content and activity. The increase in CYP2E1 
protein expression was not accompanied by any 
significant increase in mRNA expression [99]. The 
induction of CYP2E1 by isoniazid was also not 
accompanied by an increased level of CYP2E1 
mRNA, and was completely blocked by pretreatment 
with cycloheximide or sodium fluoride, inhibitors of 
mRNA translation. These data thus suggest that 
CYP2E1 induction by isoniazid is due to activation of 
CYP2E1 mRNA translation and that the hydrazide 
group on the pyridine ring of isoniazid is important 
both in the selective induction of CYP2E1 and for 
magnitude of effect [70 ]. 
Thus, xenobiotic inducers elevate CYP2E1 pro­
tein levels without any concomitant enhancement of 
corresponding mRNA. Mechanisms of CYP2E1 induc­
tion by ethanol, imidazole, dimethylsulphoxide, 2-
propanol, pyridine, isoniazid, acetone, pyrazine, and 
pyrazole may be mediated either through elevated 
mRNA translational efficiency due to higher protein 
translation rate or mRNA stabilization — or protein 
stabilization from degradation [38, 90, 91 ]. Altered 
expression of hepatic CYP2E1 by xenobiotic or phy­
siological stimuli is largely mediated through post-
transcriptional mechanisms that may include altered 
CYP2E1 mRNA translation and/or protein degra­
dation. Approximately 30—40 % of CYP2E1 mRNA 
was not associated with polysomes and therefore not 
actively engaged in protein synthesis. It is probable 
that secondary structure in the 5' UTR of CYP2E1 
mRNA is at least partially responsible for the inef­
ficient translation of this mRNA [100]. 
Regulation of CYP2E1 expression and activity. 
Many toxic compounds are activated by CYP2E1 to 
reactive metabolites representing a potential hazard 
for cellular homeostasis. Therefore, knowledge about 
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CYP2E1 regulation could be of great biological impor­
tance. Several publications were devoted to elucidation 
of mechanism of CYP2E1 expression and activity 
regulation. The regulation of the steady-state CYP-
2E1 expression and content is an extremely complex 
process and is exerted at several different cellular 
levels [7 ]. The enzyme is regulated by transcriptional 
activation, mRNA stabilization, increased mRNA 
translation and a posttranslational mechanism which 
involves enzyme stabilization and decreased protein 
degradation [7, 38]. The principal mechanism, which 
controls the induction process, depends on the che­
mical nature of the inducer, the age, and the nutri­
tional and hormonal status of the human subject. 
Moreover, it is thought that environmental factors 
induce protein in different tissues with varying 
strength resulting in considerable inter-individual va­
riation in protein level. 
The expression of CYP2E1 was found to be 
developmentally regulated. No immunodetectable pro­
tein or CYP2E1 mRNA was present in newborn rats. 
For example, the rat hepatic CYP2E1 gene becomes 
transcriptionally activated and the dramatic increase 
in mRNA level occurs within 24 h after birth [101]. 
Rapid increases in CYP2E1 mRNA and protein 
occurred within 1 week after birth in both male and 
female rats [6 ]. mRNA level increased 3-fold from 2 
to 6 days of age and remained elevated up to the age 
of 3 months in both sexes [2 ]. The increases in both 
CYP2E1 and its mRNA paralleled the change in 
aniline hydroxylase activity during development. 
Run-on transcriptional analysis confirmed that these 
increases were due to transcriptional activation of 
CYP2E1 gene [6]. It is suggested that CYP2E1 gene 
is positively regulated in adult rats by HNF-la or a 
protein similar in DNA-binding properties to HNF-
la. To date the role of this factor or other protein-
protein interactions in the lack of CYP2E1 transcrip­
tion in fetal and newborn animals remains unclear 
[101]. 
One major mode of CYP2E1 regulation is at the 
posttranscriptional level, since many low-molecular-
weight compounds stabilize the enzyme against pro­
teolysis by the proteasome complex. In an in vitro 
system containing human liver microsomes, degra­
dation of CYP2E1 in the microsomes requires addi­
tion of the human liver cytosol fraction in a reaction 
sensitive to inhibitors of the proteasome complex. It is 
not clear how CYP2E1 in the microsomal membrane 
becomes accessible to the cytosolic proteasome. 
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Since molecular chaperones play an essential role 
in protein folding and degradation, the possible role 
of heat shock proteins in CYP2E1 degradation by this 
reconstituted system was also evaluated [102]. CYP-
2E1 is regulated by the chaperone machinery and can 
be ubiquitylated by the hsp70-dependent E3 ubiquitin 
ligase CHIP. A general model was elaborated of how 
substrates, such as ethanol, can regulate the inter-
action of CYP2E1 with the chaperones bsp90 and 
hsp70 to alter enzyme turnover profoundly [103]. 
In conclusion, several different modes of CYP2E1 
regulation exist. In particular, elevated mRNA levels 
(10-fold) in subjects with diabetes and after fasting 
are due to mRNA stabilization and increase in gene 
transcription, respectively. In contrast to transcrip-
tional activation during development, stabilization of 
CYP2E1 by many exogenous low-molecular-weight 
substrates, such as ethanol and acetone, might be due 
to posttranscriptional events, appears to be a common 
mechanism by which CYP2E1 is regulated [6]. It can 
be concluded that CYP2E1 is mainly regulated at a 
posttranscriptional level. 
Regulation of CYP2E1 activity by hormones. 
CYP2E1 mRNA and protein levels are altered in 
response to pathophysiological conditions initiated by 
hormones including insulin, glucagon, growth hor-
mone, leptin and growth factors such as epidermal 
growth factor and hepatocyte growth factor, thus 
providing evidence that CYP2E1 expression is under 
tight homeostatic control [38 ]. 
Regulation of CYP2E1 by hormones occurs on 
transcriptional level since variation in protein concen-
tration correlates with mRNA level [38, 96]. Conside-
rable intensification (7-fold) of mRNA synthesis and 
protein content by glucagons was observed in primary 
cultured rat hepatocytes [96 ]. In contrast, insulin and 
growth hormone decrease mRNA synthesis and con-
tent significantly [96, 104]. It was demonstrated on 
primary cultured rat hepatocytes that decreasing the 
insulin level in the culture medium enhanced xeno-
biotic-mediated CYP2E1 expression [92]. Insulin 
produced a concentration-dependent decrease in 
CYP2E1 mRNA levels and CYP2E1 mRNA half-life 
decreased from approximately 48 hours in the ab-
sence of insulin to approximately 15 hours at 10 
nmol/1 insulin. Inhibitor wortmannin ameliorated the 
insulin-mediated decrease in CYP2E1 mRNA levels 
[96]. The relative roles of pituitary hormones (es-
pecially growth hormone) and testicular hormones 
(especially testosterone) in the regulation of hepatic 
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CYP2E1 were studied in the male rats. Depletion of 
pituitary hormones by hypophysectomy resulted in 
6-fold increases in CYP2E1 in the liver with a 
concomitant increase in CYP2E1 mRNA [105]. Gro-
wth hormone may also lead to decrease in mRNA 
levels. Available evidence suggests that the induction 
of hepatic CYP2E1 by hypophysectomy may result 
from reduced glucose utilization, and that the effect 
of growth hormone on CYP2E1 expression may be 
mediated with enhanced glucose utilization, but not 
with insulin production [104]. Thus, CYP2E1 regu-
lation occurs on transcriptional level under a variety 
of physiological and pathophysiological conditions 
such as fasting, diabetes, obesity, and non alcohol-
induced steatohepatitis. All these states are accom-
panied by several-fold increase in CYP2E1 mRNA 
and protein expression, which has been associated 
with elevated ketone bodies. The data obtained pro-
vide evidence on involvement of transcriptional and 
posttranscriptional mechanisms in the hormone-me-
diated regulation of CYP2E1. 
CYP2E1 role in ethanol metabolism. CYP2E1 
plays an important role in ethanol metabolism. Oxi-
dation of ethanol via alcohol dehydrogenase (ADH) 
explains various metabolic effects of ethanol but does 
not account for the tolerance. In case of chronic 
alcohol consumption, the existence of an additional 
pathway was suggested and then described by Lieber 
and DeCarli — namely, the microsomal ethanol oxi-
dizing system (MEOS), involving cytochrome P450. 
After chronic ethanol consumption, the activity of the 
MEOS increases considerably, that is associated with 
increase in the content of cytochrome P450, especially 
CYP2E1, although other P450s — CYP1A2 and CYP-
3A4 — are involved [27 ]. However, the mean level of 
CYP2E1-dependent ethanol oxidation in human liver 
microsomes was twice that of CYP1A2 and CYP3A4. 
Alcohol and xenobiotics share the same oxidative 
microsomal pathway, which is mainly located in the 
endoplasmic reticulum of hepatocytes. MEOS is res-
ponsible for approximately 10—15 % of ethanol 
metabolism. 
CYP2E1 is the key enzyme of the microsomal 
pathway of ethanol oxidation. The correlation of 
MEOS activity with the levels of immunoreactive 
CYP2E1 in individual human microsomes was highly 
significant (r2 = 0.88, P<0.01) [106]. 7-fold induc-
tion of CYP2E1 by ethanol was demonstrated in vivo 
[107], while 2-fold induction was observed in Fao rat 
hepatoma cells [84]. CYP2E1 is inducible by chronic 
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ethanol consumption and its activity increases 3 to 
5-fold in liver samples from alcoholics [51 ]. Ace-
taldehyde as well as ethanol is metabolized by 
CYP2E1 in the presence of NADPH. The microsomal 
acetaldehyde-oxidizing system activity was increased 
2.3-fold by giving rats ethanol [106]. Induction of 
CYP2E1 by ethanol is one of the central pathways by 
which ethanol generates a state of oxidative stress in 
hepatocytes [63]. Heavy consumption of alcohol, 
which results in CYP2E1 induction, increases in-
dividual susceptibility to the toxic or carcinogenic 
effects of various xenobiotics, in particular drugs 
[51]. CYP2E1 induction by ethanol may accelerate 
the carcinogenic action of N-nitrosodimethylamine at 
very low concentrations. Both in vitro and in vivo 
results indicate that elevated CYP2E1 level enhances 
cisplatin-induced hepatotoxicity, and the mechanism 
may involve increased production of ROS and oxi-
dative stress [108]. 
Induction of CYP2E1 in the human liver by 
ethanol. Whereas long-term ethanol consumption eli-
cits a marked increase in hepatic CYP2E1 content, 
the molecular mechanism by which ethanol produces 
this effect is the subject of controversy in animals, 
and it has not been elucidated in human beings. 
Debate still exists as to the precise mechanism of 
CYP2E1 induction by ethanol. Possible mechanisms 
have been proposed, ranging from enhanced de novo 
enzyme synthesis caused by elevated CYP2E1 mRNA 
levels, enhanced translation of preexisting mRNA or 
stabilization of CYP2E1 protein. Thus, two hypo-
theses exist on mechanism of CYP2E1 induction by 
ethanol — it may be a result of increasing protein 
synthesis [107] or consequence of CYP2E1 stabi-
lization by ethanol [90]. To evaluate these mecha-
nisms, the time course of hepatic CYP2E1 protein 
induction was examined in rats. Animals were pair-
fed liquid diets containing 36 % of total calories as 
either ethanol or dextrin-maltose (controls) for 28 
days. It was shown that induction of hepatic CYP2E1 
protein by ethanol in vivo involves increased enzyme 
synthesis rather than decreased enzyme degradation. 
This enhancement of de novo CYP2E1 synthesis most 
likely entails the ethanol-mediated increase of steady-
state levels of CYP2E1 mRNA and/or the stimulation 
of its translational efficiency [107]. 
Other authors suggest that CYP2E1 protein sta-
bilization is responsible for protein induction by 
ethanol [90, 109]. Results of experiments with chro-
nic ethanol intake reveal that induction of CYP2E1 
during chronic ethanol exposure in rats occurs by a 
complex two step mechanism [109, 110]. The first 
step of induction is associated with relatively low 
blood alcohol concentrations (<200 mg/dl), and in-
volves increases in CYP2E1-dependent activities and 
apoprotein levels with no increases in steady-state 
mRNA encoding CYP2E1 and appears to be post-
transcriptional. The second step of this process occurs 
at higher blood alcohol concentrations (>300 mg/dl) 
and involves elevated mRNA levels. It is demon-
strated that CYP2E1 induction by chronic ethanol is 
associated with increased CYP2E1 gene transcription 
[109]. At low blood alcohol concentrations a 6- to 
7-fold induction was accompanied by a 4- to 5-fold 
increase in CYP2E1 apoprotein, but no increase in 
CYP2E1 mRNA levels. In contrast, at higher blood 
alcohol concentrations, induction of p-nitrophenol hy-
droxylase was 15- to 16-fold, induction of CYP2E1 
apoprotein was 12- to 13-fold and CYP2E1 mRNA 
was elevated 5- to 6-fold [110]. It indicates that 
transcriptional activation of CYP2E1 requires the 
long-term presence of highly intoxicating ethanol 
levels. The mechanisms underlying these induction 
steps still require intense investigation. 
Mechanisms of CYP2E1 degradation. CYP2E1 is 
distinguished from other cytochrome P450 enzymes 
by its rapid intracellular turnover. Alcohol-inducible 
CYP2E1 has the most rapid turnover of any member 
of this large superfamily of membrane-bound oxy-
genases, and its degradation rate is altered pro-
foundly by various substrates [103]. 
In the absence of substrate, CYP2E1 is degraded 
with a biphasic half-life of about 6—7 h, followed by 
a slower secondary phase of about 37 h [91 ]. In 
accordance with recently obtained results, CYP2E1 
half-life in the absence of substrate in vivo varied 
from 4—7 h [62, 111] to 9 h [112]. Factors, which 
regulate rapid turnover of CYP2E1 or initiate its rapid 
degradation, are unknown. Several mechanisms for 
the rapid degradation have been postulated. Inte-
resting hypothesis is proposed on the basis of inhe-
rent CYP2E1 properties [62]. It is known that 
CYP2E1 has a high degree of oxydase activity in the 
absence of substrate, resulting in production of reac-
tive oxygen radicals. Therefore, rapid intracellular 
turnover of the enzyme may be partly due to covalent 
modifications by such radicals. NADPH-dependent 
generation of reactive oxygen radicals may evoke 
oxidative modification of CYP2E1 and labilization, 
and subsequent rapid enzyme degradation. Inactiva-
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tion of CYP2E1 may play a role in regulating the 
levels of enzyme and thereby minimize direct toxicity 
of excessive production of CYP2E1-derived ROS. 
Perhaps, other changes occur during catalytic cycling, 
in which case the inhibition of electron supply from 
NADPH-cytochrome P450 reductase would be expec-
ted to stabilize the protein. These results demonstrate 
that short half-life of CYP2E1 in vivo may be largely 
due to the rapid destabilization of the enzyme during 
catalytic cycling rather than to the intrinsic instability 
of the protein molecule. 
In the absence of substrate, CYP2E1 undergoes 
rapid degradation, which is necessary for apoprotein 
phosphorylation on serine-129. In this case, enzyme 
inactivation is followed by proteolytic degradation 
[113]. Phosphorylation serine-129 causes loss heme 
in vitro and an enhanced rate of P450IIE1 degra-
dation enzyme in hepatyocytes [91 ]. By site-directed 
mutations of the cDNA coding for CYP2E1, Serl29 
was replaced by alanine (Ala) or glycine (Gly). These 
findings argue that involvement of Serl29 and its 
phosphorylation is not in determining CYP2E1 pro-
tein level, but rather in controlling its catalytic 
activity [114]. cAMP-dependent phosphorylation of 
CYP2E1 is followed by degradation by serine pro-
teases present in the endoplasmic reticulum [62]. 
Two serine proteinases capable of digesting CYP2E1 
have been purified from sodium cholate solubilized rat 
liver microsomal membranes which indicate that the 
proteinases can degrade CYP2E1 in its native envi-
ronment [115]. It is suggested that these proteinases 
play a role in the rapid phase of cytochrome P450 
degradation in the endoplasmic reticulum. Subfrac-
tionation of microsomes revealed that the Mg(2+)-
ATP-dependent proteolytic system active on CYP2E1 
was present in both rough and smooth endoplasmic 
reticulum [112]. 
The mechanism underlying the rapid degradation 
of CYP2E1 also appears to involve the ubiquitin-
proteasome proteolytic pathway [102, 111, 116]. 
Mechanism-based inactivation of liver microsomal en-
zyme in vivo and/or in vitro, via heme modification 
of the protein, results in accelerated proteolytic deg-
radation of the enzyme that is preceded by the 
ubiquitination of the protein, thereby implicating the 
ubiquitin-ATP-dependent 26S proteasomal system 
[116]. 
The proteasome complex constitutes a major 
extra lysosomal proteolytic system which is res-
ponsible for ubiquitin-dependent pathway of intra-
cellular proteolysis. The recent studies revealed the 
involvement of the proteasomes in degradation of 
membranous endoplasmic reticulum proteins [117]. 
Using the cytosolic fraction, the formation of high 
M(r) ubiquitin-CYP2El conjugates was observed in 
vitro [111 ]. On the contrary, even in the presence of 
proteasome inhibitors high molecular weight ubiquitin 
conjugates were not observed. Mutagenesis of two 
putative ubiquitination sites (Lys317 and 324) did not 
alter the degradation of CYP2E1 [118]. 
Using PS-341, a potent proteasome inhibitor in 
vivo, it was demonstrated that CYP2E1 induced by 
ethanol is degraded by the proteasome [119]. Mo-
lecular modelling of a predicted cytosolic domain of 
CYP2E1 resulted in identification of a putative ubi-
quitination-target/substrate-interaction structure (re-
sidues 317—340). An affinity-purified antibody reac-
tive to this domain quenched CYP2E1 ubiquitination 
in a concentration-dependent manner in a rabbit 
reticulocyte lysate-based ubiquitination assay. These 
two observations suggest an association between the 
CYP2E1 cytosolic domain involved in catalysis and its 
serving as a target for ubiquitination. Thus, these 
results provide a plausible mechanistic explanation for 
the observation that substrate binding shields CYP-
2E1 protein from turnover by the ubiquitin-pro-
teasome-dependent machinery [15]. However, the 
mechanism of CYP2E1 degradation by ubiquitin-
proteasome proteolytic pathway has not been revealed 
completely. Several studies have shown the invol-
vement of molecular chaperones in protein degra-
dation [120]. The sensitivity to geldanamycin and 
molybdate and the immunodepletion experiments sug-
gest that hsp90 is one of these factors that interact 
with CYP2E1 and/or with the proteasome to promote 
the degradation of this microsomal P450 [102]. 
In the presence of ethanol, only the slower phase 
of turnover is observed. The half-life of ethanol-sta-
bilized CYP2E1 was calculated at 38 h [111]. CYP-
2E1 substrates specifically inhibited the rapid intra-
cellular degradation of CYP2E1 and also prevented 
phosphorylation and subsequent proteolysis in isola-
ted microsomes. Substrates specific for the enzyme, 
such as ethanol and imidazole bind with enzyme, 
protect the enzyme from cAMP-dependent phospho-
rylation Serl29 and from degradation in hepatocytes 
[91, 102, 112]. It is suggested that CYP2E1 is acutely 
inactivated in the endoplasmic reticulum and that 
degradation of this isozyme occurs, at least in part, 
by the lysosomal route. 
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In conclusion, CYP2E1 is of interest because of 
its ability to metabolize and activate many toxi-
cological substrates, including ethanol. Levels of CYP-
2E1 are significantly elevated by specific substrates 
and under a variety of pathophysiological conditions. 
CYP2E1 induction enhances the toxicity and carci­
nogenicity of many xenobiotics. Moreover, CYP2E1 is 
one of the major hepatic enzymes involved in the 
metabolism of procarcinogens. Therefore, investiga­
tions of CYP2E1 expression and functional activity 
are of particular importance. 
/. M. Данко, M. О. Чацин 
Структурно-функціональна характеристика цитохрому Р4502Е1 
(CYP2E1) 
Резюме 
В огляді узагальнено результати дослідження рівня експреси, і 
локалізації, структури і функціональних властивостей цито­
хрому Р4502Е1 (CYP2E1). Розглянуто механізми індукції 
синтезу і активності CYP2E1 різними за хімічною структу­
рою сполуками, а також за деяких патофізіологічних станів 
організму. Значну увагу приділено інгібіторам експресії CYP-
2Е1. Проаналізовано останні дані відносно механізмів регу­
ляції експресії CYP2E1 та його деградації 
Ключові слова: цитохром Р4502Е1 (CYP2E1), експресія, 
індуктори та інгібітори, регуляція експресії, окисний мета­
болізм етанолу. 
И. М. Данко, Н. А. Чащин 
Структурно-функциональная характеристика цитохрома 
Р4502Е1 (CYP2E1) 
Резюме 
В обзоре обобщены результаты исследования уровня экспрес­
сии и локализации, структуры и функциональных свойств 
цитохрома Р4502Е1 (CYP2E1). Рассмотрены механизмы ин­
дукции синтеза и активности CYP2E1 различными по химиче­
ской структуре соединениями, а также при некоторых пато­
физиологических состояниях организма. Значительное внима­
ние уделено ингибиторам экспрессии CYP2EL Проанализирова­
ны последние данные относительно механизмов регуляции 
экспрессии CYP2EJ и его деградации. 
Ключевые слова: цитохром Р4502Е1 (CYP2E1), экспрессия, 
индукторы и ингибиторы, регуляция экспрессии, окислитель­
ный метаболизм этанола. 
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